Fig. 2: TAS CD8 + T cell phenotype and function.
From: SPP1 + macrophages cause exhaustion of tumor-specific T cells in liver metastases
Frequency of (A) CD39 +, (C) Granzyme B +, (E) CD69+, and (G) Ki-67+ among TAS CD8+ T cells in the TIL, liver, and spleen of liver and subcutaneous tumor-bearing mice at days 7 (subcutaneous (s.q.), n = 5; intrahepatic (i.h.) tumor injection, n = 5), 14 (s.q., n = 5; i.h., n = 5) and 21(s.q., n = 5; i.h., n = 7). Comparison of (B) CD39+ (Liver p < 0.000001; TIL p = 0.000178), (D) Gzmb+ (Liver p = 0.000037; TIL p = 0.000413), (F) CD69+ (Liver p = 0.000404; TIL p = 0.012408); and (H) Ki-67+ (Liver p = 0.000032; TIL p = 0.168307) AH1 + to AH1- CD8 + T cells in the liver (left, n = 17) and TIL (right, n = 17) at day 14. I Tumor weights after either IgG or αCD8 T cell antibody treatment after intrahepatic (IgG, n = 7; αCD8, n = 8, p > 0.9999) or subcutaneous injection (IgG, n = 9; αCD8, n = 11, p = 0.0011) of tumor. All experiments (A–I) were completed in female, BALB/c 6-8 week old mice. Data was analyzed with unpaired two-sided t tests (B, D, F, H) and brown-forsythe and welch anova (I): *P < 0.05; **P < 0.01; ***P < 0.005; ****P < 0.001, ns = not significant (data are presented as mean values +/− SEM).
